Sandoz requests bond from Amgen to cover lost Zarxio sales

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) filed a statement with the U.S. Court of Appeals for the Federal Circuit (CAFC) requesting a $179.4 million bond from Amgen Inc. (NASDAQ:AMGN) to compensate for losses due to the delayed launch of Zarxio filgrastim-sndz, Sandoz's biosimilar of Amgen's Neupogen filgrastim.

Last week, the CAFC granted Amgen's motion for a preliminary injunction that will delay Zarxio's launch until the court resolves Amgen's appeal in the companies' ongoing dispute concerning their exchange of information about the biosimilar. Sandoz had previously planned to launch Zarxio on May 11 (see BioCentury Extra, May 6). ...